Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines

Michael J. Duryee, Rick A Bevins, Carmela M. Reichel, Jennifer E. Murray, Yuxiang Dong, Geoffrey Milton Thiele, Sam D. Sanderson

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Vaccines to methamphetamine (meth) were designed by covalently attaching a meth hapten (METH) to peptide constructs that contained a conformationally biased, response-selective molecular adjuvant, YSFKPMPLaR (EP54). Rats immunized with EP54-containing meth vaccines generated serum antibody titers to authentic meth, an immune outcome that altered meth self-administration. Immunization increased meth self-administration suggesting pharmacokinetic antagonism. The ability of immune sera to bind a METH-modified target protein dramatically decreased during and shortly after the meth self-administration assay, suggesting effective sequestration of free meth. However, the binding ability of immune sera to the METH-modified target protein was recovered 34 days after meth-free clearance time.

Original languageEnglish (US)
Pages (from-to)2981-2988
Number of pages8
JournalVaccine
Volume27
Issue number22
DOIs
StatePublished - May 14 2009

Keywords

  • Anti-methamphetamine antibodies
  • Conformationally biased
  • Methamphetamine vaccine
  • Molecular adjuvant
  • Response-selective C5a agonists
  • Self-administration

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines'. Together they form a unique fingerprint.

  • Cite this